Alpha Cognition (ACOG) Registration Filing summary

Company overview and business model

• Biopharmaceutical company focused on neurodegenerative diseases, notably Alzheimer's and ALS.

• Commercial launch of ZUNVEYL, a next-generation acetylcholinesterase inhibitor, in March 2025.

• ZUNVEYL targets long-term care facilities and is priced at $749/month, with Medicare positioning and strategic partnerships.

• Pipeline includes pre-clinical programs for Alzheimer's, mTBI, ALS, and SMA, with some assets intended for out-licensing.

• Exclusive licensing agreement for ZUNVEYL in Asia-Pacific with China Medical System Holdings, valued at $44 million plus royalties.

Financial performance and metrics

• Net tangible book value as of June 30, 2025: $31.49 million ($1.97/share).

• After a $75M offering at $8.26/share, adjusted net tangible book value would be $104.1 million ($4.15/share).

• Immediate dilution to new investors estimated at $4.11/share at the assumed offering price.

• 16,160,787 common shares outstanding as of August 21, 2025.

Use of proceeds and capital allocation

• Proceeds primarily allocated to marketing and sales of ZUNVEYL, working capital, and general corporate purposes.

• Management retains broad discretion over the application of net proceeds.